Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor
Molecular Therapy · 2025-02 · 33 (2) · 723-733
DOI: 10.1016/j.ymthe.2024.12.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025-02. Verfasst von Wonkyung Oh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lactic Acid, Programmed Cell Death 1 Receptor, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Purdue University Center for Cancer Research, American Foundation for Pharmaceutical Education.
Abstract (Originalsprache)
Immune checkpoint blockade therapy targeting the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has shown remarkable clinical impact in multiple cancer types. Nonetheless, despite the recent success of PD-1/PD-L1 blockade therapy, such response rates in cancer patients have been limited to tumors encompassing specific tumor microenvironment characteristics. The altered metabolic activity of cancer cells shapes the anti-tumor immune response by affecting the activity of immune cells. However, it remains mostly unknown how the altered metabolic activity of cancer cells impacts their resistance to PD-1/PD-L1 blockade therapy. Here, we found that tumor cell-derived lactic acid renders the immunosuppressive tumor microenvironment in the PD-1/PD-L1 blockade-resistant tumors by inhibiting the interaction between the PD-L1 protein and anti-PD-L1 antibody. Furthermore, we showed that the combination therapy of targeting PD-L1 with our PD-L1 antibody-drug conjugate (PD-L1-ADC) and reducing lactic acid with the monocarboxylate transporter 1 (MCT-1) inhibitor, AZD3965, can effectively treat the PD-1/PD-L1 blockade-resistant tumors. The findings of this study provide a new mechanism of how lactic acid induces an immunosuppressive tumor microenvironment and suggest a potential combination treatment to overcome the tumor resistance to PD-1/PD-L1 blockade therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.
- Department of Veterinary Clinical Science, Purdue University, West Lafayette, IN 47907, USA.
- Department of Veterinary Clinical Science, Purdue University, West Lafayette, IN 47907, USA; Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.
- Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA; Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN 47907, USA; Purdue Institute fo…
Förderung
- NCI NIH HHS
- Purdue University Center for Cancer Research
- American Foundation for Pharmaceutical Education
- National Cancer Institute
- American Cancer Society
- Purdue University Purdue Institute for Drug Discovery
- Ralph W and Grace M Showalter Research Trust Fund
- Indiana Clinical and Translational Sciences Institute
Zitieren
APA
Oh, W., Kim, A. M. J., Dhawan, D., Knapp, D. W., & Lim, S. O. (2025). Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor. Molecular Therapy, 33(2), 723-733. https://doi.org/10.1016/j.ymthe.2024.12.044
Vancouver
Oh W, Kim AMJ, Dhawan D, Knapp DW, Lim SO. Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor. Molecular Therapy. 2025;33(2):723-733. doi:10.1016/j.ymthe.2024.12.044
BibTeX
@article{Oh2025,
author = {Oh, Wonkyung and Kim, Alyssa Min Jung and Dhawan, Deepika and Knapp, Deborah W and Lim, Seung-Oe},
title = {Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {2},
pages = {723--733},
doi = {10.1016/j.ymthe.2024.12.044}
}
EUVIMED